Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Rating of “Moderate Buy” from Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $17.1111.

A number of research analysts have commented on ADPT shares. Guggenheim started coverage on Adaptive Biotechnologies in a research report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th.

Adaptive Biotechnologies Trading Down 1.3%

Shares of NASDAQ ADPT opened at $15.76 on Friday. Adaptive Biotechnologies has a 1-year low of $5.97 and a 1-year high of $20.76. The company has a 50-day moving average of $16.45 and a two-hundred day moving average of $14.29. The company has a market cap of $2.41 billion, a PE ratio of -29.18 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business had revenue of $93.97 million for the quarter, compared to analysts’ expectations of $58.76 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. Adaptive Biotechnologies’s revenue was up 102.4% compared to the same quarter last year. As a group, equities research analysts forecast that Adaptive Biotechnologies will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 124,998 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $15.59, for a total value of $1,948,718.82. Following the transaction, the chief executive officer directly owned 2,584,243 shares in the company, valued at $40,288,348.37. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert Hershberg sold 22,968 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $16.00, for a total transaction of $367,488.00. Following the sale, the director directly owned 46,722 shares of the company’s stock, valued at $747,552. This represents a 32.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,358,650 shares of company stock valued at $23,122,398 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its stake in Adaptive Biotechnologies by 46.7% in the fourth quarter. SG Americas Securities LLC now owns 99,935 shares of the company’s stock valued at $1,623,000 after buying an additional 31,822 shares during the period. Diversified Trust Co. increased its stake in shares of Adaptive Biotechnologies by 5.6% in the 4th quarter. Diversified Trust Co. now owns 42,200 shares of the company’s stock valued at $685,000 after acquiring an additional 2,224 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at approximately $187,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at approximately $238,000. Finally, Harvest Investment Services LLC boosted its stake in Adaptive Biotechnologies by 104.7% during the 3rd quarter. Harvest Investment Services LLC now owns 344,512 shares of the company’s stock worth $5,154,000 after acquiring an additional 176,235 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.